Don't you think Dr. Linda Liau saying that there should be a path to approval for what is essentilly the 90% who received treatment has merit? What if FDA was shown a definate signal of activity, historical blended OS was being beat by 3 months or more and PFS was already in hand at the "stealth interim" DMC recommendation to stop for efficacy based on primary being met with strong signal for OS at that time? I do see Dr. Linda Liau being willing to sign off on that without much coaxing at all. Best wishes.
And I will go with BLINDED being the "the data previously known as blinded" (i.e., it has been unblinded).
I think the company tries hard to be so specific with their wording, and we all try so hard to attribute every other type of meaning to it... other than what it actually says.